BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 17695457)

  • 1. Prognostic value of HER2 and progesterone receptor expression in endometrial carcinoma with positive peritoneal washing.
    Benevolo M; Vocaturo A; Novelli F; Mariani L; Vocaturo G; Cianciulli AM; Marandino F; Perrone-Donnorso R; Giannarelli D; Natali PG; Mottolese M
    Anticancer Res; 2007; 27(4C):2839-44. PubMed ID: 17695457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
    Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
    Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of the triple negative phenotype in endometrial cancer.
    Kothari R; Morrison C; Richardson D; Seward S; O'Malley D; Copeland L; Fowler J; Cohn DE
    Gynecol Oncol; 2010 Aug; 118(2):172-5. PubMed ID: 20605625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
    Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
    Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
    Suthipintawong C; Wejaranayang C; Vipupinyo C
    J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
    Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
    Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival.
    Pertschuk LP; Masood S; Simone J; Feldman JG; Fruchter RG; Axiotis CA; Greene GL
    Gynecol Oncol; 1996 Oct; 63(1):28-33. PubMed ID: 8898164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls.
    Moriki T; Takahashi T; Ueta S; Mitani M; Ichien M
    Diagn Cytopathol; 2004 Apr; 30(4):251-6. PubMed ID: 15048960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.
    Shabani N; Mylonas I; Jeschke U; Thaqi A; Kuhn C; Puchner T; Friese K
    Anticancer Res; 2007; 27(4A):2027-33. PubMed ID: 17649817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu overexpression and hormone dependency in endometrial cancer: analysis of cohort and review of literature.
    Mariani A; Sebo TJ; Katzmann JA; Riehle DL; Dowdy SC; Keeney GL; Lesnick TG; Podratz KC
    Anticancer Res; 2005; 25(4):2921-7. PubMed ID: 16080545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium.
    Orejuela FJ; Ramondetta LM; Smith J; Brown J; Lemos LB; Li Y; Hollier LM
    Gynecol Oncol; 2005 May; 97(2):483-8. PubMed ID: 15863148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
    J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up.
    Jensen KC; Turbin DA; Leung S; Miller MA; Johnson K; Norris B; Hastie T; McKinney S; Nielsen TO; Huntsman DG; Gilks CB; West RB
    Breast Cancer Res Treat; 2008 Dec; 112(3):453-9. PubMed ID: 18193353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is peritoneal cytology a prognostic factor of endometrial cancer confined to the uterus?
    Saga Y; Imai M; Jobo T; Kuramoto H; Takahashi K; Konno R; Ohwada M; Suzuki M
    Gynecol Oncol; 2006 Oct; 103(1):277-80. PubMed ID: 16678244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.